Roche touts PhII win for BTK in­hibitor in mul­ti­ple scle­ro­sis as PhI­II show­down with Sanofi, Mer­ck KGaA, No­var­tis looms

Roche is stak­ing its claim in the race to de­vel­op a BTK in­hibitor for mul­ti­ple scle­ro­sis, with a topline Phase II win show­ing its can­di­date re­duced brain le­sions.

There are no num­bers yet — Roche and its sub­sidiary Genen­tech are sav­ing those for a med­ical meet­ing — but the com­pa­nies sug­gest­ed that the pos­i­tive re­sult bodes well for the Phase III tri­als they are run­ning for in re­laps­ing MS and pri­ma­ry pro­gres­sive MS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER